11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 2, 2006, Pages 169-178

  Tang, B N T ^a   Levivier, M ^a   Heureux, M ^a   Wikler, D ^a   Massager, N ^a   Devriendt, D ^b   David, P ^a   Dumarey, N ^a   Corvilain, B ^a   Goldman, S ^a  

^a ERASME HOSPITAL   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adenomas; Methionine; PET; Pituitary; Radiosurgery

Indexed keywords

CABERGOLINE; KETOCONAZOLE; METHIONINE C 11; CARBON; DIAGNOSTIC AGENT; METHIONINE;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; GAMMA KNIFE RADIOSURGERY; HUMAN; HYPOPHYSIS ADENOMA; MALE; MEDICAL ASSESSMENT; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; RECURRENT DISEASE; ADULT; HYPOPHYSIS TUMOR; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; CARBON RADIOISOTOPES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; MIDDLE AGED; NEOPLASM, RESIDUAL; PITUITARY NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 31444437209     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1882-0     Document Type: Article

References (46)

1. Kuratsu J, Takeshima H, Ushio Y. Trends in the incidence of primary intracranial tumors in Kumamoto, Japan. Int J Clin Oncol 2001;6:183-91
2. Ferrari G, Lovaste MG, Moresco M, Rossi G. Primary intracranial tumors. Survey of incidence in the province of Trento in the years 1977-1981. Ital J Neurol Sci 1985;6:191-6
3. Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000;85:4596-602
4. Swearingen B, Barker FG II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26
5. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 2002;87:3180-6
6. Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med 1988;109:487-93
7. Davis PC, Hoffman JC Jr, Tindall GT, Braun IF. CT-surgical correlation in pituitary adenomas: evaluation in 113 patients. Am J Neuroradiol 1985;6:711-6
8. Nakane T, Kuwayama A, Watanabe M, Takahashi T, Kato T, Ichihara K, et al. Long term results of transsphenoidal adenomectomy in patients with Cushing's disease. Neurosurgery 1987;21:218-22
9. Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996;81:3084-90
10. Sano T, Yamada S. Histologic and immunohistochemical study of clinically non-functioning pituitary adenomas: special reference to gonadotropin-positive adenomas. Pathol Int 1994;44:697-703
11. Sheehan JP, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for residual or recurrent nonfunctioning pituitary adenoma. J Neurosurg 2002;97:408-14
12. Shin M. Gamma knife radiosurgery for pituitary adenoma. Biomed Pharmacother 2002;56 Suppl 1:178s-81s
13. Kremer P, Forsting M, Hamer J, Sartor K. MR imaging of residual tumor tissue after transsphenoidal surgery of hormone-inactive pituitary macroadenomas: a prospective study. Acta Neurochir Suppl 1996;65:27-30
14. Kremer P, Forsting M, Ranaei G, Wuster C, Hamer J, Sartor K, et al. Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma. Acta Neurochir (Wien) 2002;144:433-43
15. Rodriguez O, Mateos B, de la Pedraja R, Villoria R, Hernando JI, Pastor A, et al. Postoperative follow-up of pituitary adenomas after trans-sphenoidal resection: MRI and clinical correlation. Neuroradiology 1996;38:747-54
16. Steiner E, Knosp E, Herold CJ, Kramer J, Stiglbauer R, Staniszewski K, et al. Pituitary adenomas: findings of postoperative MR imaging. Radiology 1992;185:521-7
17. Kaiser WA, Steckelbroeck V, Siewert B, Layer G, Hochstetter A, Reiser M. Differentiating between tumor and implant material in the postoperative sella using MRT. Rofo 1993;158:555-64
18. Battistin L, Gerstenbrand F. PET and NMR: new perspectives in neuroimaging and in clinical neurochemistry. New York: Liss; 1986. p. 407-24
19. Bergstrom M, Muhr C, Lundberg PO, Langstrom B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 1991;32:610-5
20. 11C. Eur J Nucl Med 1976;1:11-4
21. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997;38:1459-62
22. Sakamoto Y, Takahashi M, Korogi Y, Bussaka H, Ushio Y. Normal and abnormal pituitary glands: gadopentetate dimeglumine-enhanced MR imaging. Radiology 1991;178:441-5
23. Peck WW, Dillon WP, Norman D, Newton TH, Wilson CB. High-resolution MR imaging of pituitary microadenomas at 1.5 T: experience with Cushing disease. Am J Roentgenol 1989;152:145-51
24. Cano A, Martinez M, Benito P, Tofe S, Higuera A, Munoz R. Analysis of indirect signs of microprolactinoma at MR imaging. Eur J Radiol 1999;31:157-64
25. Levivier M. Integration of metabolic data by positron emission tomography in image-guided neurosurgical interventions [in French]. Bull Mem Acad R Med Belg 2002;157:235-45; discussion 245-50
26. Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D, et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 2004;45:1146-54
27. Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S, et al. Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 2005;71:161-8
28. Yoon PH, Kim DI, Jeon P, Lee SI, Lee SK, Kim SH. Pituitary adenomas: early postoperative MR imaging after transsphenoidal resection. Am J Neuroradiol 2001;22:1097-104
29. Rajaraman V, Schulder M. Postoperative MRI appearance after transsphenoidal pituitary tumor resection. Surg Neurol 1999;52:592-8; discussion 598-9
30. Bergstrom M, Muhr C, Lundberg PO, Bergstrom K, Gee AD, Fasth KJ, et al. Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study. J Comput Assist Tomogr 1987;11:815-9
31. Muhr C, Bergstrom M. Positron emission tomography applied in the study of pituitary adenomas. J Endocrinol Invest 1991;14:509-28
32. Scippo ML, Beckers A, Frankenne F, Reznik M, Stevenaert A, Igout A, et al. Adenohypophysis hormone gene products in 14 pituitary adenomas: analysis by immunohistochemistry and northern blotting. Arch Int Physiol Biochim Biophys 1991;99:135-40
33. Jameson JL, Klibanski A, Black PM, Zervas NT, Lindell CM, Hsu DW, et al. Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas. J Clin Invest 1987;80:1472-8
34. Yeh PJ, Chen JW. Pituitary tumors: surgical and medical management. Surg Oncol 1997;6:67-92
35. Buchfelder M, Nistor R, Fahlbusch R, Huk WJ. The accuracy of CT and MR evaluation of the sella turcica for detection of adrenocorticotropic hormone-secreting adenomas in Cushing disease. Am J Neuroradiol 1993;14:1183-90
36. Levivier M, Goldman S, Bidaut LM, Luxen A, Stanus E, Przedborski S, et al. Positron emission tomography-guided stereotactic brain biopsy. Neurosurgery 1992;31:792-7; discussion 797
37. 18F]fluorodeoxyglucose. J Neurosurg 1995;82:445-52
38. Levivier M, Wikier D, Goldman S, David P, Metens T, Massager N, et al. Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: early experience with brain tumors. Technical note. J Neurosurg 2000;93 Suppl 3:233-8
39. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 1996;78:1098-106
40. Brada M, Ajithkumar TV, Minniti G. Radiosurgery for pituitary adenomas. Clin Endocrinol (Oxf) 2004;61:531-43
41. De Souza B, Brunetti A, Fulham MJ, Brooks RA, DeMichele D, Cook P, et al. Pituitary microadenomas: a PET study. Radiology 1990;177:39-44
42. 11C methionine PET scan in the pituitary gland of a patient with cerebral glioma after surgical abortion [in Japanese]. No To Shinkei 1998;50:573-7
43. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-55
44. Colao A, Lastoria S, Lombardi G. Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest 1999;22:736-7
45. 111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas. Q J Nucl Med 1995;39:90-3
46. Koga M, Nakao H, Arao M, Sato B, Noma K, Morimoto Y, et al. Demonstration of specific dopamine receptors on human pituitary adenomas. Acta Endocrinol (Copenh) 1987;114:595-602